Skip to main content

Table 2 Tumor response

From: Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination

  TACE plus apatinib plus camrelizumab (n = 80)
Best overall response
 Complete response (CR) 14 (17.5)
 Partial response (PR) 33 (41.3)
 Stable disease (SD) 18 (22.5)
 Progressive disease (PD) 15 (18.7)
ORR (CR + PR) 47 (58.8, 47.2–69.6)
DCR (CR + PR + SD) 65 (81.2, 71.0–89.1)
  1. Data are N (%)
  2. DCR disease control rate, ORR objective response rate, TACE transarterial chemoembolization